Dog filariosis in the Lazio region (Central Italy): first report on the presence of Dirofilaria repens

BACKGROUND: Epidemiological investigations were carried out in the Lazio Region to assess the status of canine filariosis and to evaluate the actual risk for veterinary and medical public health. METHODS: Since August 2001 to June 2003, a total of 972 canine blood samples, collected in public kennels and from private owners animals of the 5 Provinces of the Region, were tested. The presence of filarial parasites was evaluated by microscopy and bio-molecular techniques; the species identification was performed by means of the same diagnostic tools. RESULTS: A total of 17/972 (1.75%; 95%CI 1.06%–2.85%) blood samples were parasitized by D. repens,13 out them drawn by dogs resident in the Province of Roma, and 4 in the other provinces. Multivariate analysis was performed in order to evaluate the association between filariosis and risk factors. The origin from coastal territories seems to be a significant risk factor to acquire the infection. CONCLUSION: This is the first report of canine filariosis in the Lazio Region, where D. repens was before reported only in foxes. The risk of human zoonotic infection is stressed, and the absence of other filarial species is discusse

Efficacy evaluation of epsiprantel (Cestex®) against Echinococcus multilocularis in dogs and cats

Helminth-free dogs and cats were experimentally infected with protoscoleces of Echinococcus multilocularis and used in controlled trials for efficacy evaluation of the cestodicide epsiprantel. In two separate trials each 4 dogs were treated at day 20 post infection (p.i.) with average oral dosages of 5.1 (4.9-5.3) and 5.4 (5.2-5.8) mg/kg body weight (b.w.) epsiprantel, respectively, and necropsied at day 24 p.i. Among each 4 dogs of the two untreated control groups all animals were infected and had high intestinal worm burdens with averages of 33,575 and 100,725 E. multilocularis specimens per animal (individual worm burdens in group Ib 59,500-149,800, group IIb 20,500-43,200); in the two groups of treated dogs the average worm burdens were reduced by 99.6 and 99.9%. Among 8 treated dogs 4 were helminth-free, the other 4 had residual worm burdens (10-70 in 3 dogs, 1480 in 1 dog). In each 5 cats single oral treatments with average doses of 2.7 (2.7-2.8) and 5.5 (5.5-5.5) mg/kg b.w. epsiprantel were 100% effective against E. multilocularis 20 days p.i. and eliminated the worm burdens from all 10 animals. In the untreated group of 5 cats the average worm burden was 2864 per animal (individual worm burdens 20-6830). Side effects of the drug treatment were not observed. The results of the study show that in single therapeutic dosages recommended by the producer (dogs 5.5 mg, cats 2.75 mg/kg b.w.) epsiprantel eliminates E. multilocularis to over 99% or completely, but residual worm burdens may persist in some animals

Use of IgG- and IgM-specific ELISAs for the assessment of exposure status of chickens to Eimeria species.

Simple and reliable methods for the determination of the exposure status of chickens to Eimeria species are required. For this purpose an enzyme-linked immunosorbent assay (ELISA) detecting specific IgG and IgM antibodies in serum samples was evaluated. Sera from chickens hyperimmunized by intramuscular injection of a saline extract of Eimeria tenella sporozoites were used to determine optimal reaction conditions in the ELISA which were found to be at a serum dilution of 1:100 and an antigen concentration of 0.2 microgram per reaction well. Saline extracts of sporulated oocysts and purified sporozoites of E. tenella were also potent antigens but most studies were carried out with sporozoite antigen. In a trial with 80 chickens, concentrations of serum IgM directed against sporozoite antigen increased significantly 9 days after primary infection with 10,000 oocysts of E. tenella per animal. IgM levels subsequently decreased rapidly reaching a plateau level only slightly higher than uninfected controls by about 15 days post-infection. In chickens challenged with 10,000 oocysts 21 days after primary infection significant increases of IgM levels were observed 2, 6 and 12 days later. In contrast IgG levels increased only slightly after primary infection but significant increases occurred after challenge infection so that by Day 12 after challenge sporozoite-specific IgG levels were much higher than in control chickens. Thus, it may be possible to discriminate between chickens actually infected with Eimeria (as indicated by high levels of antiparasite IgM), chickens which have been repeatedly exposed to Eimeria (as indicated by high levels of antiparasite IgG) and unexposed birds. The applicability of this ELISA, using sporozoite antigen of E. tenella to practical situations was substantially confirmed, since sampling of over 1000 sera from commercially reared broilers and laying hens indicated that broilers, maintained on medicated food, had low levels of IgM and IgG whereas 84-97% of the laying hens, receiving drug-free feed, had relatively high IgG concentrations. These results reflect low and rare exposure to Eimeria infections in broilers and repeated exposure of the hens

Expert consensus document: Defining the major health modifiers causing atrial fibrillation: a roadmap to underpin personalized prevention and treatment

Despite remarkable advances in antiarrhythmic drugs, ablation procedures, and stroke-prevention strategies, atrial fibrillation (AF) remains an important cause of death and disability in middle-aged and elderly individuals. Unstructured management of patients with AF sharply contrasts with our detailed, although incomplete, knowledge of the mechanisms that cause AF and its complications. Altered calcium homeostasis, atrial fibrosis and ageing, ion-channel dysfunction, autonomic imbalance, fat-cell infiltration, and oxidative stress, in addition to a susceptible genetic background, contribute to the promotion, maintenance, and progression of AF. However, clinical management of patients with AF is currently guided by stroke risk parameters, AF pattern, and symptoms. In response to this apparent disconnect between the known pathophysiology of AF and clinical management, we propose a roadmap to develop a set of clinical markers that reflect the major causes of AF in patients. Thereby, the insights into the mechanisms causing AF will be transformed into a format that can underpin future personalized strategies to prevent and treat AF, ultimately informing better patient care